查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403420

2030 年短肠症候群市场预测：按诊断、治疗方法、药物类别、配销通路和地区进行的全球分析

Short Bowel Syndrome Market Forecasts to 2030 - Global Analysis By Diagnosis (Blood Tests, Imaging Procedures, Physical Exam and Other Diagnoses),Treatment, Drug Class, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球短肠症候群市场规模为 18 亿美元，预计在预测期内复合年增长率为 17.9%，到 2030 年将达到 57 亿美元。

小肠或大肠的某些部分可能会消失或停止功能，导致一种称为短肠症候群的复杂疾病。因此，小肠症候群患者经常出现吸收不良，即脂肪、碳水化合物（糖）、维生素、矿物质、微量元素和水等营养素的吸收减少。缺乏重要的维生素和矿物质可能会导致营养不良、体重意外减轻和其他症状。

根据 WebMD LLC 2021 年发布的资料，每人每年的肠外支持费用约为 65,000 美元至 320,000 美元。

促生长因素：静脉输液需求增加

患有这种疾病的患者越来越需要静脉补液以维持正常的尿流量和水合水平。由于这些患者面临的挑战，业内许多知名公司正在努力满足这项需求。由于髂骨的缺陷会导致镁吸收不良并导致低镁血症，因此许多公司开发了镁补充品来帮助患者保持充足的水分。

成长抑制因素：危险的副作用

市场面临的主要障碍是用于治疗短肠症候群的药物的副作用。 Revestive 和 Gatex 最典型的健康副作用包括头痛、噁心、呕吐、感冒和流感。此外，这些药物已被证明能够引起其他健康问题，如大肠息肉、胆囊发炎、胰臟阻塞、可能变成癌症的细胞异常发育和肠阻塞。

机会：短肠症候群的盛行率

近年来，短肠症候群变得越来越常见。给药全肠外营养的患者数量正在增加，这推动了市场的扩张。短肠症候群的发生率估计为每 100 万人 4 例，但实际发生率接近每 100 万人 3 例。接受肠外营养的大量患者预测了这种疾病的确切盛行率，但这尚不清楚。

威胁：治疗费用高

肠外营养是治疗方法这种疾病最受欢迎的方法，但价格昂贵。肠外营养治疗可以在医院或家中进行。另一方面，在家接受肠外营养的患者的治疗费用低于在医院接受肠外营养的患者。此外，用于治疗这种疾病的药物每年的高昂费用进一步限制了商业性接受度。

COVID-19 的影响

由于这项发现，短肠症候群市场的製造商正在扩大其收入前景，因为 COVID-19 患者报告出现胃肠道问题。另一方面，SBS治疗需要长期肠外营养或器官移植。因此，企业和学术界应该共同努力，进一步发展自组织工程研究领域，以实现利用患者自身细胞和组织进行治疗。公司正在增加生长激素、低动力药物和抗胰泌素药物的产量。

在预测期内，谷氨酰胺部分预计将是最大的。

预计谷氨酰胺细分市场在预测期内将达到最高水准。一种称为麸酰胺酸的胺基酸是肠道细胞的主要能源来源。麸酰胺酸支持肠道屏障功能，有助于维持肠道黏膜完整性，也可能降低肠道渗透性。它可以透过促进肠道组织修復和缩短肠道手术后的恢復期来促进癒合。

药物治疗产业预计在预测期内复合年增长率最高

预计药物治疗领域在预测期内复合年增长率最高。药物可以帮助缓解与这种疾病相关的常见症状，例如腹胀、腹泻、胃部不适和营养不良。某些药物可以透过改善营养物质和电解质的吸收来补偿肠道功能表面积的损失。这有助于防止营养不良及其后果。

比最大的地区

由于久坐生活方式的增加、医疗基础设施的改善以及政府对克隆氏症研究的资助增加，预计北美将在预测期内占据最大的市场占有率。近年来，由于久坐生活方式的发展，短肠症候群的使用显着增加，导致专注于健康用餐，垃圾食物增加。因此，肠病市场持续成长。

复合年增长率最高的地区

预计亚太地区在预测期内复合年增长率最高。该地区正经历大公司的直接存在、对新疗法市场开拓的大量研发投资以及对基于 GLP-2 的疗法的临床试验的日益重视，这些因素正在推动市场成长。推动市场扩张的主要原因是短肠症候群患者数量的显着增加（尤其是在新兴国家）、快速都市化以及政府在医疗基础设施方面的支出增加。

免费客製化服务

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 公司之间的竞争关係

第五章全球短肠症候群市场：依药物类别

  • 麸酰胺酸
  • GLP-2
  • 生长激素
  • 佐尔布蒂夫
  • 质子帮浦抑制剂
  • 组织胺阻断剂
  • 升糖素
  • 止泻
  • 其他药物类别

第六章全球短肠症候群市场：依配销通路

  • 零售药房
  • 医院药房
  • 网上销售

第七章全球短肠症候群市场：依诊断

  • 验血
  • 影像检查
    • 磁振造影(MRI)
    • 使用显影剂的X 光摄影
    • 电脑断层扫描 (CT) 扫描
  • 体检
  • 其他诊断

第八章全球短肠症候群市场：依治疗方法

  • 药品
  • 外科手术
  • 营养疗法
    • 经肠营养
    • 肠外营养
  • 移植
  • 其他治疗方法

第九章全球短肠症候群市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • VectivBio AG
  • Takeda Pharmaceutical Company Limited
  • Nutrinia
  • Merck KGaA
  • Ardelyx
  • OxThera Inc
  • Zealand Pharma
  • Nestle Health Science
  • Hanmi Pharm.Co., Ltd
  • Sancilio&Company Inc
  • Meters Biopharma
  • OPKO Health, Inc.
Product Code: SMRC24645

According to Stratistics MRC, the Global Short Bowel Syndrome Market is accounted for $1.8 billion in 2023 and is expected to reach $5.7 billion by 2030 growing at a CAGR of 17.9% during the forecast period. A part of the small or large intestine may physically disappear or cease to function, resulting in the complicated condition known as short bowel syndrome. As a result, malabsorption-the decreased absorption of nutrients such as lipids, carbohydrates (sugars), vitamins, minerals, trace elements, and fluids-occurs often in people with small bowel syndrome. Malnutrition, inadvertent weight loss, and other symptoms might result from the deficiency of vital vitamins and minerals.

According to the data published by WebMD LLC in 2021, the cost of parenteral support per person is around USD 65,000 to USD 320,000 annually.

Market Dynamics:

Driver:

Increased demand of intravenous supplementation of fluids

Patients with this disease are increasingly requiring intravenous fluid supplementation to maintain normal urine flow and hydration levels. Given that these individuals have difficulties, a number of prominent firms in the industry are attempting to address this need. Since the loss of the distal ileum results in malabsorption of magnesium, which causes hypomagnesemia, a number of firms are creating magnesium supplements to aid patients in getting enough water.

Restraint:

Dangerous side effects

The main obstacle facing the market is the adverse effects of medications used to treat short bowel syndrome. The most typical side effects of Revestive or Gattex on health include headaches, nausea, vomiting, colds, and flu. Furthermore, it has been shown that these medications may result in other health issues such colon polyps, gallbladder inflammation, pancreatic obstruction, aberrant cell development that may result in cancer, and intestinal blockage.

Opportunity:

Prevalence of short bowel syndrome

Short bowel syndrome has become more common in recent years. The number of patients receiving complete parenteral nutrition is growing, which has fueled market expansion. The estimated incidence of short bowel syndrome is four cases per million, although actual incidence is closer to three cases per million. Given the amount of patients receiving parenteral nourishment, the disease's precise prevalence is predicted, despite the lack of clarity in this regard.

Threat:

High treatment cost

The most popular therapy for treating this illness is parenteral feeding, which comes with a high expense for the entire course of care. Both in-hospital and at-home environments can perform this treatment. On the other hand, compared to patients getting parenteral nourishment in hospitals, the cost of care for those receiving it at home is lower. Furthermore, the prohibitive yearly expense of the medications used to treat this illness further restricts their commercial acceptance.

COVID-19 Impact:

Manufacturers in the short bowel syndrome market are expanding their income prospects as a result of the results, since individuals with COVID-19 have reported experiencing gastrointestinal issues. On the other hand, long-term parenteral feeding or an organ transplant are necessary for the SBS therapy. Thus, businesses and academics ought to work together to further the field of autologous tissue engineering research, which enables patients to be treated with their own cells or tissues. Businesses are increasing their production of growth hormones, hypomotility drugs and anti-secretin medicines.

The glutamine segment is expected to be the largest during the forecast period

The glutamine segment is expected to be the largest during the forecast period. An amino acid called glutamine is the main energy source for the intestinal lining cells. It supports the operation of the gut barrier, aids in preserving the integrity of the intestinal mucosa, and may even lessen intestinal permeability. By encouraging the repair of the intestinal tissues and shortening the recovery period following intestinal surgery, it may facilitate recuperation.

The medications segment is expected to have the highest CAGR during the forecast period

The medications segment is expected to have the highest CAGR during the forecast period. Drugs can aid in the relief of symptoms including bloating, diarrhea, stomach discomfort, and nutritional deficits that are frequently linked to this illness. Certain drugs can make up for the decreased functional surface area of the gut by improving the absorption of nutrients and electrolytes. This aids in the prevention of malnutrition and its consequences.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the increased sedentary lifestyle, increased healthcare infrastructure, and rising funding from the government on the research of Crohn's disease, among others. The use of short bowel syndrome has expanded significantly in recent years due to the development in sedentary lifestyles, which have left people with less time to focus on eating wholesome foods and more junk food. As a result, the market for intestinal diseases has continued to grow.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The market is growing in this area due to the direct presence of large companies, significant R&D investments in the development of novel medications, and an increasing emphasis on clinical trials for GLP-2-based therapies. The primary reasons propelling the market expansion are the notable increase in short bowel syndrome cases, especially in emerging nations, rapid urbanization, and rising government spending on healthcare infrastructure.

Key players in the market:

Some of the key players in Short Bowel Syndrome market include VectivBio AG, Takeda Pharmaceutical Company Limited, Nutrinia, Merck KGaA, Ardelyx, OxThera Inc, Zealand Pharma, Nestle Health Science, Hanmi Pharm.Co., Ltd, Sancilio&Company Inc, Meters Biopharma and OPKO Health, Inc.

Key Developments:

In September 2022, Zealand Pharma A/S announced positive results from a phase 3 trial of Glepaglutide for treatment of short bowel syndrome. Glepaglutide is the potential best-in-class long-acting GLP-2 analog. The candidate has distinct advantages over Teduglutide, including once-weekly dosing and a longer half-life.

In March 2022, VectivBio AG announced a licensing agreement with Asahi Kasei Pharma Corporation to commercialize and develop apraglutide in Japan, which is used to treat SBS.

Diagnoses Covered:

  • Blood Tests
  • Imaging Procedures
  • Physical Exam
  • Other Diagnoses

Treatments Covered:

  • Medications
  • Surgery
  • Nutritional Therapy
  • Transplant
  • Other Treatments

Drug Classes Covered:

  • Glutamine
  • GLP-2
  • Growth Hormone
  • Zorbtive
  • Proton Pump Inhibitors
  • Histamine Blockers
  • Glucagon
  • Anti-Diarrheals
  • Other Drug Classes

Distribution Channels Covered:

  • Medications
  • Surgery
  • Nutritional Therapy
  • Transplant
  • Other Treatments

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Short Bowel Syndrome Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Glutamine
  • 5.3 GLP-2
  • 5.4 Growth Hormone
  • 5.5 Zorbtive
  • 5.6 Proton Pump Inhibitors
  • 5.7 Histamine Blockers
  • 5.8 Glucagon
  • 5.9 Anti-Diarrheals
  • 5.10 Other Drug Classes

6 Global Short Bowel Syndrome Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Retail Pharmacies
  • 6.3 Hospital Pharmacies
  • 6.4 Online Sales

7 Global Short Bowel Syndrome Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Blood Tests
  • 7.3 Imaging Procedures
    • 7.3.1 Magnetic Resonance Imaging (MRI)
    • 7.3.2 X-ray with a Contrast Material
    • 7.3.2 Computerized Tomography (CT) Scan
  • 7.4 Physical Exam
  • 7.5 Other Diagnoses

8 Global Short Bowel Syndrome Market, By Treatment

  • 8.1 Introduction
  • 8.2 Medications
  • 8.3 Surgery
  • 8.4 Nutritional Therapy
    • 8.4.1 Enteral Nutrition
    • 8.4.2 Parenteral Nutrition
  • 8.5 Transplant
  • 8.6 Other Treatments

9 Global Short Bowel Syndrome Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 VectivBio AG
  • 11.2 Takeda Pharmaceutical Company Limited
  • 11.3 Nutrinia
  • 11.4 Merck KGaA
  • 11.5 Ardelyx
  • 11.6 OxThera Inc
  • 11.7 Zealand Pharma
  • 11.8 Nestle Health Science
  • 11.9 Hanmi Pharm.Co., Ltd
  • 11.10 Sancilio&Company Inc
  • 11.11 Meters Biopharma
  • 11.12 OPKO Health, Inc.

List of Tables

  • Table 1 Global Short Bowel Syndrome Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Short Bowel Syndrome Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Short Bowel Syndrome Market Outlook, By Glutamine (2021-2030) ($MN)
  • Table 4 Global Short Bowel Syndrome Market Outlook, By GLP-2 (2021-2030) ($MN)
  • Table 5 Global Short Bowel Syndrome Market Outlook, By Growth Hormone (2021-2030) ($MN)
  • Table 6 Global Short Bowel Syndrome Market Outlook, By Zorbtive (2021-2030) ($MN)
  • Table 7 Global Short Bowel Syndrome Market Outlook, By Proton Pump Inhibitors (2021-2030) ($MN)
  • Table 8 Global Short Bowel Syndrome Market Outlook, By Histamine Blockers (2021-2030) ($MN)
  • Table 9 Global Short Bowel Syndrome Market Outlook, By Glucagon (2021-2030) ($MN)
  • Table 10 Global Short Bowel Syndrome Market Outlook, By Anti-Diarrheals (2021-2030) ($MN)
  • Table 11 Global Short Bowel Syndrome Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 12 Global Short Bowel Syndrome Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Short Bowel Syndrome Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Short Bowel Syndrome Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 15 Global Short Bowel Syndrome Market Outlook, By Online Sales (2021-2030) ($MN)
  • Table 16 Global Short Bowel Syndrome Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 17 Global Short Bowel Syndrome Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 18 Global Short Bowel Syndrome Market Outlook, By Imaging Procedures (2021-2030) ($MN)
  • Table 19 Global Short Bowel Syndrome Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 20 Global Short Bowel Syndrome Market Outlook, By X-ray with a Contrast Material (2021-2030) ($MN)
  • Table 21 Global Short Bowel Syndrome Market Outlook, By Computerized Tomography (CT) Scan (2021-2030) ($MN)
  • Table 22 Global Short Bowel Syndrome Market Outlook, By Physical Exam (2021-2030) ($MN)
  • Table 23 Global Short Bowel Syndrome Market Outlook, By Other Diagnoses (2021-2030) ($MN)
  • Table 24 Global Short Bowel Syndrome Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 25 Global Short Bowel Syndrome Market Outlook, By Medications (2021-2030) ($MN)
  • Table 26 Global Short Bowel Syndrome Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 27 Global Short Bowel Syndrome Market Outlook, By Nutritional Therapy (2021-2030) ($MN)
  • Table 28 Global Short Bowel Syndrome Market Outlook, By Enteral Nutrition (2021-2030) ($MN)
  • Table 29 Global Short Bowel Syndrome Market Outlook, By Parenteral Nutrition (2021-2030) ($MN)
  • Table 30 Global Short Bowel Syndrome Market Outlook, By Transplant (2021-2030) ($MN)
  • Table 31 Global Short Bowel Syndrome Market Outlook, By Other Treatments (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.